CN101310013B - 人平滑肌细胞的获得方法及其用途 - Google Patents

人平滑肌细胞的获得方法及其用途 Download PDF

Info

Publication number
CN101310013B
CN101310013B CN2006800428874A CN200680042887A CN101310013B CN 101310013 B CN101310013 B CN 101310013B CN 2006800428874 A CN2006800428874 A CN 2006800428874A CN 200680042887 A CN200680042887 A CN 200680042887A CN 101310013 B CN101310013 B CN 101310013B
Authority
CN
China
Prior art keywords
human
cells
medium
cell
muscle cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800428874A
Other languages
English (en)
Chinese (zh)
Other versions
CN101310013A (zh
Inventor
索菲·勒里库瑟
玛丽-诺乐·拉卡萨尼
让-皮埃尔·马若里奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute Of Vascular And Blood Research
Assistance Publique Hopitaux de Paris APHP
Original Assignee
Institute Of Vascular And Blood Research
Assistance Publique Hopitaux de Paris APHP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Vascular And Blood Research, Assistance Publique Hopitaux de Paris APHP filed Critical Institute Of Vascular And Blood Research
Publication of CN101310013A publication Critical patent/CN101310013A/zh
Application granted granted Critical
Publication of CN101310013B publication Critical patent/CN101310013B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0661—Smooth muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1323—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from skeletal muscle cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Excavating Of Shafts Or Tunnels (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2006800428874A 2005-09-19 2006-09-19 人平滑肌细胞的获得方法及其用途 Expired - Fee Related CN101310013B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0509557 2005-09-19
FR0509557A FR2890977A1 (fr) 2005-09-19 2005-09-19 Procede d'obtention de cellules musculaires lisses humaines et leurs applications
PCT/FR2006/002144 WO2007034069A1 (fr) 2005-09-19 2006-09-19 Procede d'obtention de cellules musculaires lisses humaines et leurs applications

Publications (2)

Publication Number Publication Date
CN101310013A CN101310013A (zh) 2008-11-19
CN101310013B true CN101310013B (zh) 2011-09-07

Family

ID=36587333

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800428874A Expired - Fee Related CN101310013B (zh) 2005-09-19 2006-09-19 人平滑肌细胞的获得方法及其用途

Country Status (10)

Country Link
US (1) US20090269310A1 (enExample)
EP (1) EP1934333B9 (enExample)
JP (1) JP2009508511A (enExample)
CN (1) CN101310013B (enExample)
AT (1) ATE531791T1 (enExample)
AU (1) AU2006293814B2 (enExample)
CA (1) CA2622916A1 (enExample)
FR (1) FR2890977A1 (enExample)
IL (1) IL190289A0 (enExample)
WO (1) WO2007034069A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2909559B1 (fr) * 2006-12-06 2012-09-07 Inst Vaisseaux Et Du Sang Preparations cellulaires pour une utilisation comme agent stimulant la revascularisation
KR101724639B1 (ko) * 2008-11-04 2017-04-07 리젠메드 (케이만) 엘티디. 세포-지지체 구조물
HRP20230474T1 (hr) * 2017-12-14 2023-07-21 Innovacell Ag Postupci za dobivanje stanica izvedenih iz mišića
CN112119155A (zh) * 2018-05-08 2020-12-22 苏黎士大学 用于无异种产生hMPC群的方法
EP4397752A3 (en) * 2019-03-22 2024-10-02 Innovacell GmbH Methods for obtaining induced smooth muscle cells
CN120418415A (zh) * 2022-12-28 2025-08-01 因特斯迪姆株式会社 细胞组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2810045B1 (fr) * 2000-06-07 2004-09-03 Assist Publ Hopitaux De Paris Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations
US20040247575A1 (en) * 2003-06-03 2004-12-09 Caplice Noel M. Smooth muscle progenitor cells

Also Published As

Publication number Publication date
AU2006293814B2 (en) 2011-09-29
FR2890977A1 (fr) 2007-03-23
US20090269310A1 (en) 2009-10-29
EP1934333A1 (fr) 2008-06-25
CA2622916A1 (fr) 2007-03-29
IL190289A0 (en) 2011-08-01
ATE531791T1 (de) 2011-11-15
CN101310013A (zh) 2008-11-19
EP1934333B1 (fr) 2011-11-02
JP2009508511A (ja) 2009-03-05
AU2006293814A1 (en) 2007-03-29
EP1934333B9 (fr) 2012-05-02
WO2007034069A1 (fr) 2007-03-29

Similar Documents

Publication Publication Date Title
JP5710574B2 (ja) ヒト骨髄由来内皮前駆細胞の同定、及び虚血性傷害後の心筋細胞の機能を改善するためのヒト骨髄由来内皮前駆細胞の使用
Gojo et al. In vivo cardiovasculogenesis by direct injection of isolated adult mesenchymal stem cells
Hou et al. Transplantation of mesenchymal stem cells from human bone marrow improves damaged heart function in rats
CN1822846B (zh) 血管周围间充质前体细胞诱导的血管形成
Kocher et al. Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function
JP5371445B2 (ja) 脂肪組織由来細胞を培養する方法及びその使用
Shiota et al. Isolation and characterization of bone marrow-derived mesenchymal progenitor cells with myogenic and neuronal properties
Mangi et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts
Christoforou et al. Stem cells and their potential in cell-based cardiac therapies
Burlacu et al. Promoting effect of 5-azacytidine on the myogenic differentiation of bone marrow stromal cells
WO2001048151A1 (en) Cells capable of differentiating into heart muscle cells
Itescu et al. Myocardial neovascularization by adult bone marrow-derived angioblasts: strategies for improvement of cardiomyocyte function
JP2009531021A (ja) 骨格筋周囲血管芽細胞および心筋中胚葉性血管芽細胞、それらの単離および使用方法
Bonaros et al. Combined transplantation of skeletal myoblasts and angiopoietic progenitor cells reduces infarct size and apoptosis and improves cardiac function in chronic ischemic heart failure
US20220160776A1 (en) Method for treating or preventing gastrointestinal bleeding
CN101310013B (zh) 人平滑肌细胞的获得方法及其用途
Itescu et al. Myocardial neovascularization by adult bone marrow-derived angioblasts: strategies for improvement of cardiomyocyte function
JP2009508511A5 (enExample)
WO2001048150A1 (en) Cells capable of differentiating into heart muscle cells
EP3013945B1 (en) Cortical bone-derived stem cells
AMRUTHA et al. Use of Stem Cells In Regenerative Cardiovascular Medicine
Galiñanes Bone Marrow Derived Stem Cells for Myocardial Regeneration: Clinical Experience, Surgical Delivery
Rosenthal et al. Stem cells and the regenerating heart
Fazel Cardiac repair and not regeneration after myocardial infarction: the role and therapeutic utility of the c-kitSCF pathway.
Virmani et al. Mechanistic insights into cardiac stem cell therapy from a histopathologic perspective

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110907

Termination date: 20120919